

Rapid improvement of Henoch-Schonlein purpura associated with the treatment of *Helicobacter pylori* infection

Turgay Ulas, Irfan Tursun¹, Mehmet Sinan Dal², Mehmet Ali Eren, Hakan Buyukhatipoglu³

Departments of Internal Medicine, Harran University School of Medicine, Sanliurfa, ¹Internal Medicine, Igdir Training and Research Hospital, Igdir, ²Internal Medicine, Dicle University School of Medicine, Diyarbakir, ³Internal Medicine, Division of Medical Oncology, Gaziantep University School of Medicine, Gaziantep, Turkey

Helicobacter pylori (*H. pylori*) are one of the most common bacterial infections, seen in humans, worldwide and their possible relationships to different diseases are a focus of attention nowadays. *H. pylori* may cause some extra intestinal manifestations some of which are dermatological conditions, including Henoch-Schönlein purpura (HSP), chronic urticaria and atopic dermatitis. We describe a 49-year-old man who presented with HSP triggered by gastric *H. pylori* infection. Treatment of *H. Pylori* infection was accompanied by prompt resolution of the gastrointestinal manifestations and purpuric rashes. These findings suggest a causative role for *H. pylori* in the occurrence of HSP.

Keywords: Eradication therapy, helicobacter pylori, schonlein-henoch purpura

INTRODUCTION

Henoch-Schonlein-purpura (HSP) is a systemic vasculitis, also known as a leukocytoclastic vasculitis of small vessels, resulting in skin, joint, gastrointestinal and renal involvement. HSP may affect both infants and adults, but much rarer in adults than in children. The pathogenesis of HSP remains poorly understood, but it is postulated that an unknown antigenic stimulus causes elevation of circulating IgA and that complement activation leads to necrotizing vasculitis, and a wide variety of conditions such as bacterial or viral infections, vaccinations, drugs and other environmental exposures may be responsible for the onset.^[1-4] Gastrointestinal manifestations, such as colicky abdominal pain, nausea, vomiting, and occult or massive gastrointestinal bleeding, are common. It is known that HSP is generally a self-limited condition that lasts an average of four weeks. In children the prognosis is good, as HSP typically resolves rapidly and without complication. In adults, however, the prognosis of HSP and duration

of the disease depends on the clinical features such as a higher rate of severe, atypical gastrointestinal problems; and delayed renal complications.^[1-4] *Helicobacter pylori* (*H. pylori*) has been implicated in the pathogenesis of various extra-digestive disorders. However, a few previous reports have described an association between gastric *H. pylori* infection and HSP and indicated the efficacy of eradication therapy.^[3-7] In this report, we describe an adult onset of HSP triggered by *H. pylori* positive gastritis and aimed to present this coexisting in terms of contributing to the literature. The patient was successfully treated by *H. pylori* eradication therapy.

CASE REPORT

A previously healthy 49-year-old-man was admitted to Harran University Faculty of Medicine Hospital, at Sanliurfa/Turkey in 2011, because of a one-week history of intermittent colicky abdominal pain, decreased appetite and subsequent purpura on his lower extremities. Physical examination revealed numerous erythematous macules, red-brown purpuric papules, and plaques on the legs, thighs, buttocks, and extensor surfaces of the arms [Figure 1]. On admission, his temperature was 36.9°C, pulse 76, respiration 14, and blood pressure 120/70 mmHg. Aside from mid-epigastric pain to palpation and had a previously known of vitiligo history that comprises the extremities, the remainder of the physical examination was unremarkable. Laboratory studies showed a

Access this article online	
Quick Response Code:	Website: www.journals.mui.ac.ir/jrms
	DOI: ***

Address for correspondence: Dr. Turgay Ulas, Department of Internal Medicine, Harran University School of Medicine, Yenisehir Campus - 63000, Sanliurfa, Turkey. E-mail: turgayulas@yahoo.com

Received: 03-07-2012; **Revised:** 04-08-2012; **Accepted:** 25-08-2012

white blood cell count of $23.070/\text{mm}^3$. The hemoglobin concentration was 13.07 g/dL , the platelet count was $393.200/\text{mm}^3$, elevated level of erythrocyte sedimentation rate, while normal results for serum creatinine level, serum IgA level. Urinalysis revealed microscopic hematuria and proteinuria ($450 \text{ mg}/24 \text{ hrs}$). Occult blood was found in the feces. Antinuclear antibody, rheumatoid factor, C3 was not detected and C3 levels was normal. Serologic tests for Human immunodeficiency virus and hepatitis virus (A, B, and C), were also negative. Upper endoscopy revealed findings of antrum predominant pangastritis, with erythema, and active peptic ulcer and showed patchy petechial hemorrhage of the duodenal bulb. Rapid urease test for *H. pylori* showed a positive result. Endoscopic biopsy specimens obtained from gastric mucosa revealed chronic active gastritis and multiple *H. pylori* organisms were detected within the lumina of antrum. The results of colonoscopy were negative. A biopsy specimen obtained from purpuric lesion showed a dermal perivascular and interstitial infiltrate rich in lymphocytes and neutrophils, as well as extravasations of erythrocytes and leukocytoclasia. Vessel walls showed endothelial swelling and necrosis with deposition of fibrinoid material [Figure 2]. The patient was treated with methylprednisolone 1 mg/kg/day for 10 days regarding to the abdominal complaints, urinalysis results, and age onset; however his complaints were not healed with this treatment. Further, the patient received a two-week treatment course consisting of lansoprazole 30 mg twice daily, amoxicillin 1000 mg twice daily, and clarithromycin 500 mg twice daily without steroid treatment. After the treatment, the abdominal manifestations dramatically subsided within three days and the purpuric skin lesions resolve within four days and by one week after starting the rash had completely resolved without further treatment. Stool test performed two months after the therapy showed a negative result, which suggested successful *H. pylori* eradication. The patient has had no recurrence of rash or abdominal pain, during the one year follow-up while being monitored from the outpatient clinic [Figure 3].

DISCUSSION

This report suggests that *H. pylori* infection may be a precipitating factor in the development of HSP and treatment of the *H. Pylori* infection was accompanied by rapid improvement of the HSP.

H. pylori infection may lead extradigestive consequences directly or indirectly, in various ways. A marked local and a chronic systemic immune response are triggered by *H. pylori* infection.^[8] This bacterium has been associated with certain extra-digestive dermatological conditions, including chronic urticaria, rosacea, HSP, Sweet syndrome, systemic sclerosis, and atopic dermatitis.^[9] Reinauer *et al*, described the first case




Figure 1: Numerous purpuric rashes on both lower extremities




Figure 2: Skin biopsy specimen shows perivascular neutrophilic and lymphocytic infiltrate with leukocytoclasia and erythrocyte extravasation (H and E, $\times 400$)



Figure 3: Appearance of the limbs after the *H. Pylori* infection therapy

of HSP associated with gastric *H. Pylori* infection in 1995. The symptoms of HSP disappeared after *H. Pylori* eradication therapy, and then recurred 10 months later due to reinfection with *H. Pylori*. These clinical manifestations faded again

after the second eradication treatment.^[3] Since then, some similar case reports have been described.^[4-7] More recently, Novak *et al*, found serum antibody to *H. pylori* in 10 of 11 adults with HSP compared with 11 of 20 adult controls.^[10]

In general, gastrointestinal symptoms, such as colicky abdominal pain, frequently occur in patients with *H. pylori* infection as well as in patients with HSP.^[11] Although the association of *H. pylori* infection with HSP may be underestimated, because endoscopic examination is not systematically performed in patients with HSP. Patients with HSP are treated supportively or symptomatically because of the self-limited nature, and it is evident that not all HSP patients need early steroid treatment, and treatment should be targeted at patients who have a high risk of renal involvement or severe extra renal symptoms. These risk factors are age over six years, severe abdominal pain and renal symptoms at onset. However, the effect of steroids on the prevention or treatment of renal complications has been controversial, and recurrences could be seen.^[12] In our case *H. pylori* infection was confirmed in the gastric mucosa by rapid urease test and study of endoscopic biopsy specimens, and the skin lesions were resolved promptly following the treatment of *H. pylori* infection, without the corticosteroid treatment. Regarding this successful *H. pylori* eradication treatment and no recurrence was shown within a one year follow-up, the possibly diagnosis was considered HSP associated with *H. pylori* infection.

In conclusion, *H. pylori* may be an etiological factor in pathogenesis of HSP and upper endoscopy and *H. pylori* examination should be considered to confirm the presence of gastric *H. pylori* infection. Also, HSP patients should be considered to evaluate the usefulness of *H. pylori* eradication therapy, especially with serious gastrointestinal manifestations. To address this study, further studies must focus on this relationship.

REFERENCES

1. Lawee D. Atypical clinical course of Henoch-Schonlein purpura. *Can Fam Physician* 2008;54:1117-20.
2. Saulsbury FT. Henoch-Schönlein purpura. *Curr Opin Rheumatol* 2010;22:598-602.
3. Reinauer S, Megahed M, Goerz G, Ruzicka T, Borchard F, Susanto F, *et al*. Schönlein-Henoch purpura associated with gastric Helicobacter pylori infection. *J Am Acad Dermatol* 1995;33:876-9.
4. Hoshino C. Adult onset Schönlein-Henoch purpura associated with Helicobacter pylori infection. *Intern Med* 2009;48:847-51.
5. Machel L, Vaillant L, Machel MC, Büchler M, Lorette G. Schönlein-Henoch purpura associated with gastric Helicobacter pylori infection. *Dermatology* 1997;194:86.
6. Mozrzymas R, d'Amore ES, Montini G, Guariso G. Schönlein-Henoch vasculitis and chronic Helicobacter pylori associated gastritis and duodenal ulcer: A case report. *Pediatr Med Chir* 1997;19:467-8.
7. Cecchi R, Torelli E. Schönlein-Henoch purpura in association with duodenal ulcer and gastric Helicobacter pylori infection. *J Dermatol* 1998;25:482-4.
8. Aydogan T, Ulas T, Selcoki Y, Alkan R, Yılmaz OC, Yalcın KS, *et al*. Effects of Helicobacter pylori eradication on proteinuria: A prospective study. *Wien Klin Wochenschr* 2012;124:241-4.
9. Abdel Hafez HZ, Mahran AM, Hofny EM, Attallah DA, Sayed DS, Rashed H. Alopecia areata is not associated with Helicobacter pylori. *Indian J Dermatol* 2009;54:17-9.
10. Novak J, Szekanecz Z, Sebesi J, Takáts A, Demeter P, Bene L, *et al*. Elevated levels of anti-Helicobacter pylori antibodies in Henoch-Schonlein purpura. *Autoimmunity* 2003;36:307-11.
11. Fiedorek SC, Casteel HB, Pumphrey CL, Evans DJ Jr, Evans DG, Klein PD, *et al*. The role of Helicobacter pylori in recurrent, functional abdominal pain in children. *Am J Gastroenterol* 1992;87:347-9.
12. Ronkainen J, Koskimies O, Ala-Houhala M, Antikainen M, Merenmies J, Rajantie J, *et al*. Early prednisone therapy in Henoch-Schonlein purpura: A randomized, double blind, placebo-controlled trial. *J Pediatr* 2006;149:241-7.

How to cite this article: Ulas T, Tursun I, Dal MS, Eren MA, Buyukhatipoglu H. Rapid improvement of Henoch-Schonlein purpura associated with the treatment of Helicobacter pylori infection. *J Res Med Sci* 2012;17:1086-8.

Source of Support: Nil, **Conflict of Interest:** None declared.